✦ LIBER ✦

An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia

✍ Scribed by Lawrence J. Ettinger; Joanne Kurtzberg; P. A. Voǔte; Herbert Jürgens; Steven L Halpern

Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 574 KB
Volume: 75
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19950301)75:5<1176::aid-cncr2820750519>3.0.co;2-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination therapy with methotrexate, v

Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia

✍ Alvaro Aguayo; Jorge Cortes; Deborah Thomas; Sherry Pierce; Michael Keating; Hag 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

BACKGROUND. L-asparaginase in combination with methotrexate has synergistic antileukemic activity in a schedule-dependent fashion. A new preparation of L-asparaginase, polyethylene-glycol conjugated (PEG)-asparaginase, is a pharmacologically different formulation of L-asparaginase with distinct prop

An isocratic fluorescence HPLC assay for

An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia

✍ Christa E. Nath; Luciano Dallapozza; Adam E. Eslick; Ashish Misra; Deborah Carr; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 358 KB 👁 1 views

## Abstract A novel assay for the determination of l‐asparaginase activity in human plasma is described that is based on the HPLC quantitation of l‐aspartic acid produced during enzyme incubation. Methods for monitoring l‐asparagine depletion are also described. Chromatography of l‐aspartic acid, l

Prospective comparison of two flow cytom

Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia

✍ Drorit Luria; Eti Rosenthal; David Steinberg; Yona Kodman; Marina Safanaiev; Nin 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB 👁 1 views

Long-term efficacy and safety of etanerc

Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open-label, extended-treatment trial

✍ Daniel J. Lovell; Edward H. Giannini; Andreas Reiff; Olcay Y. Jones; Rayfel Schn 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views

Expanding Nilotinib Access in Clinical T

Expanding Nilotinib Access in Clinical Trials (ENACT) : An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase

✍ Franck E. Nicolini; Anna Turkina; Zhi-Xiang Shen; Neil Gallagher; Saengsuree Joo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 2 views

## Abstract ## BACKGROUND: Nilotinib is a selective, potent BCR‐ABL inhibitor. Previous studies demonstrated the efficacy and safety of nilotinib in Philadelphia chromosome‐positive chronic myeloid leukemia patients in chronic phase (CML‐CP) or accelerated phase who failed prior imatinib. ## METH